


# Remdesivir (GS-5734): A Failed Ebola Drug is now in the Clinical Trial to Fight 2019 Novel Coronavirus (2019n-CoV)



by

**Sitong Wu**

**Friday, March 6, 2020**

**1 - 1:50 P.M. | AGM-102**

## Abstract

In December 2019, an epidemic pneumonia caused by an unknown pathogen emerged in Wuhan, China. In January 7th, 2020, this pathogen was identified as “2019 Novel Coronavirus (2019n-CoV)”. As of February 25th, 2020, 81,209 confirmed cases and 2761 deaths were reported worldwide by World Health Organization (WHO). Remdesivir, developed by Gilead Sciences Inc., is a monophosphoramidate prodrug of an adenosine analogue and targets viral RNA-dependent RNA polymerase. Originally developed for Ebola virus disease, Remdesivir has also been demonstrated by Gilead to exhibit broad-spectrum antiviral activities and to have potential in treating known coronavirus in animal models. Remdesivir is currently under the clinical trials to fight the deadly 2019n-CoV virus at the University of Nebraska Medical Center (UNMC) and in China. This seminar will cover the discovery and development of remdesivir, as well as its synthesis pathway.